IDEAYA Biosciences has raised $94 million in Series B funding to drive multiple clinical studies in 2019. Source: BioSpace

The Wall Street Journal speculated today that it won't be long before drug manufacturers start consolidating in order to improve their bottom lines. Source: BioSpace

Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout. Source: BioSpace

A U.S. Food and Drug Administration announced their decision to slap a clinical hold on Solid Biosciences Inc.’s experimental gene therapy treatment for Duchenne muscular dystrophy. Source: BioSpace

Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. Source: BioSpace

Elizabeth Holmes, the founder of embattled biotech Theranos, and former company president Sunny Balwani have been charged with massive fraud by the U.S. Securities and Exchange Commission. Source: BioSpace

On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly's re-submission for their moderate-to-severe rheumatoid arthritis drug. Source: BioSpace

Federal right-to-try legislation that would have allowed terminally ill patients access to experimental therapies without approval from the U.S. Food and Drug Administration failed to muster enough support in the…

Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals has secured $63.5 million in Series B financing. Source: BioSpace

Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work. Source: BioSpace